Sanofi (NASDAQ:SNY) Coverage Initiated at BNP Paribas

Equities researchers at BNP Paribas initiated coverage on shares of Sanofi (NASDAQ:SNY) in a report released on Tuesday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $65.00 price target on the stock. BNP Paribas’ target price points to a potential upside of 27.28% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $63.33.

Sanofi Trading Down 1.5 %

NASDAQ:SNY traded down $0.77 during trading hours on Tuesday, hitting $51.07. 2,447,493 shares of the company were exchanged, compared to its average volume of 2,329,360. The stock has a market capitalization of $129.02 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a fifty day simple moving average of $54.94 and a 200 day simple moving average of $52.31. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanofi

A number of hedge funds have recently added to or reduced their stakes in SNY. Sanibel Captiva Trust Company Inc. bought a new position in shares of Sanofi in the 1st quarter worth $208,000. SG Americas Securities LLC grew its holdings in shares of Sanofi by 57.8% during the first quarter. SG Americas Securities LLC now owns 28,411 shares of the company’s stock valued at $1,576,000 after buying an additional 10,403 shares during the last quarter. Parsons Capital Management Inc. RI increased its position in shares of Sanofi by 11.8% during the first quarter. Parsons Capital Management Inc. RI now owns 14,715 shares of the company’s stock worth $816,000 after acquiring an additional 1,550 shares in the last quarter. Simplicity Wealth LLC acquired a new stake in shares of Sanofi in the 1st quarter worth about $221,000. Finally, GAMMA Investing LLC lifted its position in Sanofi by 58.7% in the 1st quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock valued at $336,000 after acquiring an additional 2,241 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.